Home > Cardiology > HFA 2022 > HELIOS-A: Vutrisiran meets exploratory endpoints

HELIOS-A: Vutrisiran meets exploratory endpoints

Presented By
Dr Pablo García-Pavía, Hospital Universitario Puerta de Hierro Majadahonda, Spain
Conference
HFA 2022
Trial
Phase 3, HELIOS-A
The 18-months results of the HELIOS-A study showed that vutrisiran treatment improved NT-proBNP levels, with a trend towards improvement in echocardiographic parameters, compared with placebo. These benefits were observed in the general population and the prespecified cardiac subpopulation of the trial. Additionally, results from scintigraphy suggested potential regression of cardiac amyloid. “Hereditary transthyretin amyloidosis (hATTR) is a rare, debilitating, and fatal disease,” introduced Dr Pablo García-Pavía (Hospital Universitario Puerta de Hierro Majadahonda, Spain) [1]. Vutrisiran is an investigational, subcutaneously administered small interfering RNA interface therapy for treating ATTR amyloidosis [2]. In the phase 3 HELIOS-A trial (NCT03759379), vutrisiran was compared with patisiran, an RNA interface therapy, administered via intravenous infusion and a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on